OTTAWA, ON / ACCESSWIRE / September 11, 2020 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the appointment of Jean-Francois Boily, CPA, CA, as Chief Financial Officer and member of the Company’s executive team. He will join the Company on September 14th bringing vast experience in publicly traded companies (TSX and NASDAQ listed) in the pharmaceutical, manufacturing and science and technology sectors.
Mr. Boily takes over from Sabino Di Paola CPA, CA who joined Tetra in 2019 and supported the effort to finance Tetra’s clinical operations and recent graduation from the TSXV to the TSX. Dr. Guy Chamberland, CEO and CRO stated, “Sabino was dedicated to the growth of Tetra, leaving no stone unturned, to ensure we raised the capital needed. On behalf of Tetra and the Board of Directors, we thank him for his financial expertise at a critical time in Tetra’s evolution and wish him great success in his future endeavours
Jean-François is a seasoned Financial Executive with over 15 years of relevant experience including executive positions in clinical research organizations, the core of Tetra’s research and development activities. In addition, he has worked in several pharmaceutical companies where he built an excellent reputation in developing financial relationships, raising capital, satisfying financial obligations, ensuring record control, merger and acquisitions, strategy, and evaluation. As a member of Tetra’s executive team, Jean-Francois will support the Company’s ambitious growth strategy and future graduation.
“I look forward to working together with Jean-Francois to build Tetra into a successful pharmaceutical company. His extensive experience in our sector, along with NASDAQ experience, is exactly what we need to ensure our growth,” said Dr. Chamberland.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX:TBP) (OTCQB:TBPMF), is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a FDA and a Health Canada approved clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.:
Tetra Bio-Pharma Inc
Dr. Guy Chamberland, M.Sc., Ph.D.
Chief Executive Officer
Phone: + 1 (833) 977-7575
Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256
SOURCE: Tetra Bio-Pharma
View source version on accesswire.com: